Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Severe Haemophilia A
Interventions
DRUG

Pharmacokinetic based dosage change

Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation

Trial Locations (1)

RG24 9NA

Basingstoke & North Hampshire Hospital, Basingstoke

All Listed Sponsors
collaborator

University of Wales Cardiff United Kingdom (UK)

UNKNOWN

collaborator

Uppsala University

OTHER

lead

Hampshire Hospitals NHS Foundation Trust

OTHER

NCT02697370 - Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A | Biotech Hunter | Biotech Hunter